Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249665 | 1.00 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL14860189 | 1.00 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL14859955 | 1.00 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL3414301 | 1.00 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL253429 | 1.00 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL252984 | 0.93 | TDP1 (0.37) | TDP1ALDH1A1LMNAGAA | |
| SCHEMBL251262 | 0.90 | TDP1 (0.36) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL251261 | 0.90 | TDP1 (0.36) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL252645 | 0.88 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA | |
| SCHEMBL252646 | 0.88 | TDP1 (0.34) | TDP1ALDH1A1ALOX15PIK3CDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588469-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012003271-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | TDP1 2619/4885ALDH1A1 3452/4885ALOX15 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.